Sunshine Guojian Pharmaceutical (Shanghai) Co has a current ratio of 21.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
SHSE:688336's Current Ratio is ranked better than 93.54% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs SHSE:688336: 21.99
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sunshine Guojian Pharmaceutical (Shanghai) Co Current Ratio Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Current Ratio Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co Current Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Current Ratio of 21.99 as of Mar. 2026. This is 119% above median its historical median of 10.06. Over the past decade, Sunshine Guojian Pharmaceutical (Shanghai) Co's Current Ratio has ranged from 2.05 to 21.99. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #91 out of 1409 companies in the Biotechnology industry, placing it in the top 6.5%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Current Ratio too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Current Ratio of 21.99 is 119% above median its 10-year median of 10.06. Over the past 10 years, this metric has ranged from a low of 2.05 to a high of 21.99. The Biotechnology industry median Current Ratio is 3.89. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 21.99 is 465.3% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #91 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #91 out of 1409 companies for Current Ratio. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the top 7% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 21.99 is 465.3% above this benchmark. Historically, Sunshine Guojian Pharmaceutical (Shanghai) Co's own Current Ratio has ranged from 2.05 to 21.99 over the past decade. While the company's 10-year median is 10.06 vs. the industry median of 3.89, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Current Ratio of 21.99 is 465.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Current Ratio is 21.99, which is 119% above median its own 10-year median of 10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.88, compared to a current price of ¥52.71 — trading 21.2% below its estimated fair value. The current Current Ratio is 21.99, which is 119% above median its 10-year median of 10.06 and 465.3% above the Biotechnology industry median of 3.89. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Current Ratio is 21.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥52.71 is trading 21.2% below its estimated GF Value™ of ¥66.88.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688336:
Current Ratio: 21.99 (119% above median its 10-year median of 10.06)
GF Value™: ¥66.88 vs. price of ¥52.71 (21.2% below fair value)
Industry Position: 465.3% above the Biotechnology median (#91 of 1409)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
84GF Score
Get the complete analysis for SHSE:688336
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
